| Prev Close | 152.14 |
| Open | 152.15 |
| Day Low/High | 151.93 / 153.69 |
| 52 Wk Low/High | 67.81 / 119.90 |
| Volume | 307.72K |
| Avg Volume | 307.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 44.10M |
| Market Cap | 6.78B |
| EPS | 1.20 |
| P/E Ratio | 90.41 |
| Div & Yield | N.A. (N.A) |
Latest News
Pumped Up About Abiomed Collar Play
The producer of heart pumps also is an interesting name for the longer term.
Abiomed Announces Q1 FY 2018 Revenue Of $132.5 Million, Up 29% Over Prior Year
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance
Heart Recovery Patients Visit Capitol Hill To Advocate For Lifesaving Cardiovascular Technology
Patients recovered their native hearts with the help of Impella®, the world's smallest heart pump
Abiomed Introduces 3rd Generation Impella CP® Heart Pumps At SCAI 2017
Designed to Enable Ease of Use in High-Risk Percutaneous Coronary Interventions and in the ICU
Abiomed Marks Grand Opening Of Newly-Expanded Headquarters In Danvers, Massachusetts
Governor Baker joins heart recovery leader for grand opening of new manufacturing and training space that represents major investment in Massachusetts
Abiomed's Impella® Technology Showcased At 2017 American College Of Cardiology Scientific Session With More Than 10 Presentations
First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program
New Study Finds Abiomed Impella® Heart Pump Reduces Injury To Kidneys During High-Risk Percutaneous Coronary Intervention
Circulation Research paper supports previously published randomized clinical trial data
Masimo's Stock Is a Great Buy Right Now
This patient-monitoring device-maker has plenty of room for growth.
Abiomed Surpasses 50,000 Impella® Patients Treated In The United States
Milestone Highlights Significant Unmet Need for Treatment Options Among Advanced Heart Failure Patients
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:
Abiomed Celebrates 2017 American Heart Month
Leader in heart recovery technology highlights stories of women whose health and quality of life have been improved by Impella® heart pump
Abiomed Announces Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year
Largest Quarterly Sequential Revenue Increase in Company History
Abiomed Announces Preliminary Q3 FY 2017 Revenue Of $114.7 Million, Up 34% Over Prior Year
Largest Quarterly Sequential Revenue Increase in Company History
Abiomed Impella CP Receives Expanded FDA Approval For High-Risk Percutaneous Coronary Intervention (PCI) Procedures
Impella 2.5, CP and 5.0 Only FDA Approved Percutaneous Heart Pumps Deemed Safe and Effective
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DLR, ESXB, IART, NMR, PBIB, PLNT, SANW, TCK Downgrades: AAN, ABMD, AXTA, CMC, CMPR, CVI, CVRR, DSPG, EHTH, ESSA, FCFS, NPTN, NWS, UHT, VDSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Abiomed Receives FDA IDE Approval For Initiation Of Door To Unloading (DTU) Prospective Feasibility Study
Study Evaluates the Safety and Feasibility of Unloading of the Left Ventricle with Impella CP® in STEMI Patients, without Cardiogenic Shock
